$ATYR
aTyr Pharma Inc

2015 Q3 Form 10-Q Financial Statement

#000119312515288119 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.570M $3.400M $1.730M
YoY Change 96.15% 96.53%
% of Gross Profit
Research & Development $7.739M $7.502M $3.638M
YoY Change 75.49% 106.21%
% of Gross Profit
Depreciation & Amortization $220.0K $210.0K $210.0K
YoY Change 4.76% 0.0%
% of Gross Profit
Operating Expenses $11.31M $10.90M $5.363M
YoY Change 81.56% 103.21%
Operating Profit -$11.31M -$10.90M -$5.363M
YoY Change 81.56% 103.21%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$16.00K -$182.0K -$225.0K
YoY Change -96.0% -19.11%
Pretax Income -$11.33M -$11.08M -$5.590M
YoY Change 70.89% 98.21%
Income Tax
% Of Pretax Income
Net Earnings -$11.33M -$11.08M -$5.588M
YoY Change 70.85% 98.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$6.704M -$6.556M -$3.472M
COMMON SHARES
Basic Shares Outstanding 23.64M shares 23.63M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.8M $103.0M
YoY Change 362.98%
Cash & Equivalents $60.05M $63.07M $24.64M
Short-Term Investments $48.80M $39.90M
Other Short-Term Assets $2.600M $3.200M
YoY Change 333.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $111.4M $106.2M
YoY Change 364.09%
LONG-TERM ASSETS
Property, Plant & Equipment $1.841M $2.022M
YoY Change -12.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $28.00M $44.70M
YoY Change
Other Assets $137.0K $146.0K
YoY Change -77.17%
Total Long-Term Assets $29.99M $46.91M
YoY Change 971.0%
TOTAL ASSETS
Total Short-Term Assets $111.4M $106.2M
Total Long-Term Assets $29.99M $46.91M
Total Assets $141.4M $153.1M
YoY Change 427.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.590M $3.002M
YoY Change 32.5%
Accrued Expenses $3.569M $2.817M
YoY Change 11.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.300M $3.200M
YoY Change -35.29%
Total Short-Term Liabilities $8.776M $9.372M
YoY Change -15.62%
LONG-TERM LIABILITIES
Long-Term Debt $2.600M $3.500M
YoY Change -55.93%
Other Long-Term Liabilities $585.0K $588.0K
YoY Change -26.88%
Total Long-Term Liabilities $585.0K $588.0K
YoY Change -91.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.776M $9.372M
Total Long-Term Liabilities $585.0K $588.0K
Total Liabilities $9.361M $9.960M
YoY Change -52.24%
SHAREHOLDERS EQUITY
Retained Earnings -$141.6M -$130.3M
YoY Change
Common Stock $270.9M $269.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.2M $139.3M
YoY Change
Total Liabilities & Shareholders Equity $141.4M $153.1M
YoY Change 427.5%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$11.33M -$11.08M -$5.588M
YoY Change 70.85% 98.28%
Depreciation, Depletion And Amortization $220.0K $210.0K $210.0K
YoY Change 4.76% 0.0%
Cash From Operating Activities -$9.460M -$11.21M -$4.900M
YoY Change 63.95% 128.78%
INVESTING ACTIVITIES
Capital Expenditures -$390.0K -$40.00K -$40.00K
YoY Change 0.0%
Acquisitions
YoY Change
Other Investing Activities $7.620M -$84.92M $0.00
YoY Change 1072.31%
Cash From Investing Activities $7.240M -$84.97M -$40.00K
YoY Change 1013.85% 212325.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -790.0K 104.7M 5.060M
YoY Change 2.6% 1969.76%
NET CHANGE
Cash From Operating Activities -9.460M -11.21M -4.900M
Cash From Investing Activities 7.240M -84.97M -40.00K
Cash From Financing Activities -790.0K 104.7M 5.060M
Net Change In Cash -3.010M 8.550M 120.0K
YoY Change -48.9% 7025.0%
FREE CASH FLOW
Cash From Operating Activities -$9.460M -$11.21M -$4.900M
Capital Expenditures -$390.0K -$40.00K -$40.00K
Free Cash Flow -$9.070M -$11.17M -$4.860M
YoY Change 57.19% 129.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36457000
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
73487415 shares
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1514471 shares
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-91010000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
335000
CY2014Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
5142000
CY2014Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
95619000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
295000
CY2014Q4 us-gaap Loans Payable Current
LoansPayableCurrent
3134000
CY2015Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95500000 shares
CY2014Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
95619000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
445000
CY2014Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2000000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1433000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2932000
CY2015Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
7285456 shares
CY2015Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3813021 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23639280 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.70
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23639280 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.60
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
909880 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
75772871 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11053954 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
909880 shares
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
73487415 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
19209000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110151000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20644000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10113000
CY2014Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
319000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2210000
CY2014Q4 us-gaap Assets
Assets
20644000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1925000
CY2014Q4 us-gaap Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock
ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock
69000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
16509000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
656000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
1954000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23639280 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24636000
CY2015Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2015Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2395288 shares
us-gaap Operating Income Loss
OperatingIncomeLoss
-11293000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-388000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-15000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11681000
us-gaap Share Based Compensation
ShareBasedCompensation
312000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
277000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
85000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
610000
CY2015Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
269725000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1140000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
139341000
CY2015Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
588000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
299000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3002000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2817000
CY2015Q2 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
3489000
CY2015Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2015Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
305000
CY2015Q2 us-gaap Loans Payable Current
LoansPayableCurrent
3248000
CY2015Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
291000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-130302000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153081000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
24000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9372000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-106000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
231000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
146000
CY2015Q2 us-gaap Assets
Assets
153081000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2022000
CY2015Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
69311000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
106175000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3218000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63066000
CY2015Q2 us-gaap Short Term Investments
ShortTermInvestments
39891000
CY2015Q2 us-gaap Long Term Investments
LongTermInvestments
44738000
CY2015Q2 life Number Of Variable Interest Entities
NumberOfVariableInterestEntities
6 Entity
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11245000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
67354 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0214 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-14.69
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10444550 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1110 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
814030 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5397000
us-gaap Net Income Loss
NetIncomeLoss
-11681000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11958000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11821000
us-gaap Operating Expenses
OperatingExpenses
11293000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5646000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5070000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8026000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
70000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-353000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
312000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3267000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
155000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
411000
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-136000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17495000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
68886 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2774 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.53
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1190110 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On May 5, 2015, the Company filed an amendment to its amended and restated certificate of incorporation to effect a one-for-7.95413 reverse stock split of the Company's common stock (the Reverse Stock Split). The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the Reverse Stock Split.
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.25
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.35
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA INC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1050045 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.87
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
7.95413 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
166454 shares
dei Trading Symbol
TradingSymbol
LIFE
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7955973 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
163000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
84927000
us-gaap Net Income Loss
NetIncomeLoss
-20151000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20166000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1497000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1419000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5725000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19820000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-331000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-192000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-106000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20257000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
us-gaap Repayments Of Bank Debt
RepaymentsOfBankDebt
1598000
us-gaap Share Based Compensation
ShareBasedCompensation
1419000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-29000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
49167000
us-gaap Operating Expenses
OperatingExpenses
19820000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-83136000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
75617000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
149798000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14095000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
533000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
717000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
168000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1954000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
418000
us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
110000
life Noncancellable Operating Leases Term Of Expiration
NoncancellableOperatingLeasesTermOfExpiration
2017-05
life Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
77246000
life Available For Sale Securities Contractual Maturity Period
AvailableForSaleSecuritiesContractualMaturityPeriod
P2Y
life Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
344000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3638000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
165000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1725000
CY2015Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
65351 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1190110 shares
life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-144000
CY2015Q2 us-gaap Interest Paid
InterestPaid
500000
CY2015Q2 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2011Q4 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P5Y
CY2014Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
66830 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.85
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10444550 shares
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
836533 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-5588000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5727000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5363000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-225000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5588000
CY2014Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
139000
CY2014Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
5363000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14901473 shares
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-11080000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11095000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10898000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-182000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-106000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11186000
CY2015Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
CY2015Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
10898000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7502000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
816000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3396000

Files In Submission

Name View Source Status
0001193125-15-288119-index-headers.html Edgar Link pending
0001193125-15-288119-index.html Edgar Link pending
0001193125-15-288119.txt Edgar Link pending
0001193125-15-288119-xbrl.zip Edgar Link pending
d59201d10q.htm Edgar Link pending
d59201dex101.htm Edgar Link pending
d59201dex311.htm Edgar Link pending
d59201dex312.htm Edgar Link pending
d59201dex321.htm Edgar Link pending
d59201dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-20150630.xml Edgar Link completed
life-20150630.xsd Edgar Link pending
life-20150630_cal.xml Edgar Link unprocessable
life-20150630_def.xml Edgar Link unprocessable
life-20150630_lab.xml Edgar Link unprocessable
life-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending